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Abstract
The use of specific immunoglobulin heavy chain variable region (VH) genes has been associated
with increased patient survival in human B-cell lymphomas (hBCL). Given the similarity of
human and canine BCL (cBCL) in morphology and clinical treatment, we examined the choice of
VH in cBCL and determined whether VH gene selection was a distinct feature associated with
survival time in dogs. VH gene selection and mutational status in 52 cBCL, including 29 diffuse
large B-cell lymphomas (cDLBCL, the most common subtype of cBCL), were analyzed by
comparison with the 80 published canine germline VH gene sequences. We further examined the
prognostic impact of the subgroups defined by these features on canine survival. We found that
VH1-44 was preferentially expressed in the majority of the 52 cBCLs (60%) as well as in the
majority of the cDLBCL subset (59%). VH1-44 gene expression was associated with a statistically
better overall survival (p=0.039) in cBCL patients, as well as in the cDLBCL subset of patients
(p=0.038). These findings suggest that VH gene selection in cBCL is not random and may
therefore have functional implications for cBCL lymphomagenesis, in addition to being a useful
prognostic biomarker.
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Diffuse large B-cell lymphoma (DLBCL), which accounts for ~50% and ~73% of hBCL and
cBCL (Ponce et al., 2010), respectively, is the most common type of mature B-cell
lymphoma in both humans and dogs. Canine patients are an attractive animal model to study
the etiology and clinical therapy of BCL because of their close phylogenetic relationship
with humans and the occurrence of spontaneous tumors in these animals (Laura Marconato,
2012). The value of dogs as a reliable BCL/DLBCL model depends on the similarity of
pathological mechanisms shared at the molecular level between human and canine patients,
and these similarities are just beginning to be explored.
Mature BCL, which arises from B cells transformed at various developmental stages,
maintains molecular features of the cell of origin, including unique VH gene rearrangement
and often, constitutive NF-κB activation (Davis et al., 2001). Molecular analysis of VH
genes in hBCL reveals valuable information about the stage of differentiation that the B cell
has reached prior to malignant transformation and also about the preferential use of specific
VH genes (Lossos et al., 2000a; Lossos et al., 2000b). For example, hDLBCL with and
without ongoing mutations in VH genes are suggested to arise from one of two distinct cell
types: germinal center (GC) and post-GC lymphocytes, respectively (Lossos et al., 2000a).
The VH gene is formed by combinatorial permutations of different V, D, and J gene
segments chosen from the VH gene repertoire and joined by addition or deletion of short
coding sequences at the VD and DJ joints to increase diversity for positive antigen-driven
selection (Das et al., 2008). VDJ recombination occurs prior to germinal center entry. VH
gene usage is not random; biased VH gene usage has been reported in normal B-cell
populations (Brezinschek et al., 1997), as well as in patients with several subtypes of hBCL,
such as preferential VH3-21 use in mantle cell lymphoma (MCL) patients (Walsh et al.,
2003) and overuse of VH4-34 in DLBCL patients (Davis et al., 2001; Gaurnier-Hausser et
al., 2011; Hsu and Levy, 1995). MCL patients with lymphomas using VH3-21 also have
longer survival times than those using other VH genes (Walsh et al., 2003). This biased
usage of certain VH genes in hBCL can reflect selective pressures that occur before and/or
after malignant transformation.
The canine VH gene repertoire includes 80 VH, 6 DH, and 3 JH segments (Bao et al., 2010;
Das et al., 2008). VH1-62 (27.0%) and VH1-44 (23.4%) were the most frequently used VH
gene clone sequences in splenic B cells (Bao et al., 2010). All other VH genes were used
with less than 11.7% frequency. Based on sequence homology, canine VH genes are divided
into 3 VH families (VH1, VH2, and VH3) each sharing at least 70% homology among
family members. The vast majority of VH genes (76) belong to the VH1 family while
VH2-51, VH2-64, and VH2-66 belong to the VH2 family. VH3-80 is the only VH3 family
member. Compared to the seven human VH gene families by sequence similarity, the canine
VH1 family is similar to the human VH3 family, which is also the largest family; and the
canine VH2 and VH3 are most similar to the human VH1 and VH4 families, respectively.
Our previous analysis of VH gene mutation status in cBCL has demonstrated the presence of
two subgroups – one with and another without ongoing somatic mutations, comparable to
hDLBCL (Richards et al., 2013). Here, we further investigated VH gene usage in cBCL and
its potential prognostic impact. Since molecular differences between cBCL histologic
subtypes have not been fully identified, we also analyzed the DLBCL subgroup separately,
to determine if their properties were similar to cBCL as a whole. Our findings elucidate
similarities in the usage of VH genes between hBCL and cBCL, with a particular focus on
DLBCL and effects of VH gene usage on canine patient survival. This molecular analysis
highlights the genetic similarity between human and canine lymphomagenesis, promoting
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the value of the canine model in clinical trials, drug development, and molecular analysis of
hBCL.
2. Materials and methods
2.1. Canine samples
Patient samples were collected by lymph node biopsies obtained from canine patients, with
owner consent, presenting with clinical signs and hematologic abnormalities consistent with
BCL/DLBCL to the Veterinary Health Complex at the North Carolina State College of
Veterinary Medicine (NCSU-VHC). The protocol was approved by the Institutional Animal
Care and Use Committee of North Carolina State University. A diagnosis was made based
on a morphological evaluation of immunohistochemistry and/or flow cytometry using
CD79a, CD3 (AbD Serotec, Raleigh, NC), and PAX5 (Leica Microsystems, Wetzlar,
Germany) antibodies, which cross-reacted appropriately in positive and negative control
canine tissues. CD79a was a marker for B-cell lymphomas; CD3, for T-cell lymphomas; and
PAX5, for pre-B and B-cell lymphomas. A sample was considered positive if over 30% of
the tumor cells were stained with antibodies. Twenty-nine samples had excisional biopsies
with lymph node effacement with diffuse sheets of large B cells by hematoxylin and eosin
(H&E) staining and were morphologically characterized as cDLBCL. A more detailed
description of samples has been described previously (Richards et al., 2013).
2.2 PCR amplification and subclone sequencing
A total of 52 BCL canine patients, including 29 DLBCLs, were sequenced and analyzed for
VH gene usage by subcloning of the PCR products. Lymphoma tissue from each sample was
isolated and frozen in Trizol (Invitrogen, Carlsbad, CA) at −80°C until extraction. RNA
extraction was performed per manufacturer's protocol and then purified over an RNeasy
column (Qiagen, Valencia, CA). For each sample, 1 µg of RNA was reverse transcribed to
cDNA using an oligo-d(T) primer and a first-strand cDNA synthesis kit (Roche,
Indianapolis, IN) and used as a template for conventional PCR. Primers were designed to
amplify a 432-base-pair region starting from the start of the IGHV open reading frame to the
JH section (forward primer sequence: 5’-CCATGGAGTCTGTGCTCTGC-3’; reverse
primer sequence : 5’-CTGAGGAGACGGTGACCAGG-3’). The PCR product was
confirmed by agarose gel electrophoresis with ethidium bromide staining. In this study,
primers were designed to amplify only VH genes in the canine VH1 family (76 of 80 genes
are in the VH1 family), and these primers successfully amplified 52/53 canine lymphoma
samples. PCR products were then cloned into plasmid DNA vectors and transformed into
E.coli using Zero Blunt TOPO PCR cloning kit (Invitrogen, Carlsbad, CA) or the TOPO II
cloning kit (Invitrogen, Carlsbad, CA). For each sample, 8 to 27 colonies containing
plasmids with the appropriate sized insert were selected for sequencing at the University of
North Carolina Genomic Analysis Core Facility (Chapel Hill, NC) (Supplementary S1).
2.3 Analysis of VH gene sequences
ViroBLAST (Deng et al., 2007) was used to identify the germline VH gene present in
patient samples by BLASTing the clone sequences against the 80 germline VH genes in the
canine VH repertoire (Bao et al., 2010). Each individual clone was assigned to the closest
germline VH gene by sequence similarity. For each sample, the most frequently used VH
gene segment was then considered as the germline VH gene used in the cell of origin, and
the degree of homology was defined by the average percentage identity for all the clones
compared to the designated germline VH gene. If the homology of a case was less than 98%
compared with the germline, the VH gene was defined as mutated (Walsh and Rosenquist,
2005).
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In order to evaluate the prognostic impact of VH gene usage on the overall survival (OS)
and progression-free survival (PFS) of canine BCL/DLBCL patients, the Kaplan-Meier
method was used to estimate survival distribution, and the survival curves were examined by
the log-rank test. P-values ≤ 0.05 were considered to be significant. Statistical calculations
were performed using R, version 2.12.1.
3. Results
3.1. Mutational status and VH gene usage in canine BCL/DLBCL
Of the 52 cBCL cases, the similarity averages were all <98% compared to the germline VH
sequences, suggesting that all had become mutated via somatic hypermutation (SHM).
Somatic hypermutation in VH genes is a hallmark of germinal center (GC) entry, so we
inferred that these lymphomas were derived from either GC or post-GC stages.
There were eight VH genes identified in the 52 cBCL cases, VH1-44(n=31), VH1-62(n=5),
VH1-77(n=5), VH1-41(n=4), VH1-47(n=3), VH1-79(n=2), VH1-48(n=1), and
VH1-35(n=1) (Table 1). The average similarity of the eight germline VH genes identified
ranged from 89.0% to 93.4%. The frequency of VH1-44 usage (59.6%) was six times higher
than that of the next most frequently used VH genes, VH1-62 (9.6%) and VH1-77 (9.6%).
We observed a noticeable bias in the use of the VH1-44 gene among the 52 cases (31/52), so
we compared this proportion to the number of VH1-44 clones identified in B-cells from
three normal dogs (26/111 clones) (Bao et al., 2010), and found a significant difference (p<.
0002, chi-square test). We analyzed a subset of the cBCLs based on histological
classification (Richards et al., 2013), examining the cDLBCL subset separately to determine
if the results were similar. VH1-44 was also the most frequently used VH gene found in the
cDLBCL subset, used in 17 out of 29 cases (58.6%). This frequency was also much higher
than the second and third most frequently used genes, VH1-77 (13.8%) and VH1-41
(10.3%).
3.2. Comparison of VH gene usage in dogs and humans
Since canine VH1-44 was the most commonly used VH gene in cBCL/DLBCL and also
frequently found in normal cells, we examined the distribution of VH gene usage in human
patients and normal B-cell populations from published studies in order to determine whether
its ortholog was also being predominantly used in humans. The most frequently used VH
genes in human DLBCL were VH4-34 (8.6–28.3%) and VH3-23 (10.3–15%) (Table 1)
(Lossos et al., 2000b; Ruminy et al., 2011), and the most frequent VH gene in human normal
B-cell populations was VH3-23 (>11%) (Brezinschek et al., 1997). Based on sequence
homology, the canine VH1 family corresponds to the human VH3 family, and the VH genes
of most cBCL cases in this study belonged to this family, with human VH3-23 having the
highest homology (89% identical) with canine VH1-44. Although it is difficult to identify
the specific human VH gene that is derived from the same ancestral gene as canine VH1-44,
canine VH1-44 is most likely orthologous to human VH3-23, VH3-33, VH3-21, and VH3-
NL1 based on sequence similarity (Table 2). Interestingly, since the VH3-23 gene is
commonly used in human normal and lymphoma B cells, this VH gene family in both
humans and dogs may share the same function in both normal B-cell development and
lymphomagenesis.
The orthologs of the human VH4 family, including VH4-34, were rarely found in the canine
VH gene repertoire. The canine VH gene most homologous to the human VH4 family was
VH3-80, with a similarity between canine VH3-80 and human VH4-34 of only 77%.
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3.3. Association between VH1-44 usage and canine survival
To determine the prognostic impact of VH1-44 gene usage on canine survival, we divided
canine patients into a VH1-44 group and a non-VH1-44 group for both BCL and DLBCL
datasets, and determined whether there was a statistically significant survival difference
between the two groups. For both BCL and DLBCL, the canine patients with lymphomas
derived from cells expressing VH1-44 had a significantly longer OS than those not
expressing VH1-44 (Table 3 and Figure 1). For the 52 BCLs, median OS for the VH1-44
group was 505 days, which was 2.4 fold higher than the non-VH1-44 group (215 days,
p=0.039). The hazard ratio (HR) was 0.514, indicating that 48.6% lower incidence of death
for the VH1-44 group compared with the non-VH1-44 group. Although the PFS for the
VH1-44 group was 1.4 fold longer than the non-VH1-44 group, it was not statistically
significant (p=0.175). Similar findings were also observed when analyzing the subset of 29
DLBCLs. The median OS for the VH1-44 group was 493 days, which was 2.7 fold higher
than the non-VH1-44 group (182 days, p=0.038). The HR was 0.405, indicating that 59.5%
lower incidence of death for the VH1-44 group compared with the non-VH1-44 group. The
median PFS for the VH1-44 group was 210 days, which was 1.5 fold higher than the non-
VH1-44 group, although this was not statistically significant (p=0.126) (Table 3).
4. Discussion
We found that the canine VH gene VH1-44 was overrepresented in cBCL relative to normal
B cells (Bao et al., 2010), and that the use of the VH1-44 gene in cBCL was associated with
better OS, but not PFS. Results were similar, both in VH1-44 frequency and survival
analysis, whether all cBCL or just the subset of known cDLBCL were analyzed, indicating
similar effects of VH gene usage across cBCL subtypes.
Bias in VH gene usage in humans has been associated with many diseases and disease
outcomes. For instance, the use of specific VH genes has been associated with autoimmunity
(Deckmyn et al., 1994; Elagib et al., 1999; Fang et al., 1994; Roark et al., 2002; Silberstein
et al., 1991; Stevenson et al., 1993). In hairy cell leukemia (HCL), lymphocytes expressing
VH4-34 were less susceptible to checkpoints for clonal deletion, resulting in a poorer
prognosis (Arons and Kreitman, 2011; Arons et al., 2009). In MCL, the use of human
VH3-21 was reported to influence the use of a specific λ light chain, Vλ3–19, and patients
with this combination had a better survival (Walsh et al., 2003). A bias in VH gene usage
has been found in hDLBCL, but VH gene usage was not associated with patient survival
(Lossos et al., 2000b). Presumably, these biases exist, both in humans and in our study of
cBCL, because certain VH genes provide a survival advantage to cells during
lymphomagenesis. We speculate that VH1-44 could lead to improved overall survival in
patients due to differential B-cell receptor/apoptosis signaling, resulting in increased
susceptibility to chemotherapeutic agents and/or less aggressive lymphoma growth.
This study has several limitations that should be considered when interpreting our results.
First, the dogs used in our study were not uniformly treated with the same chemotherapeutic
regimen. Second, canine overall survival time is impacted by other factors such as owner
preferences rather than disease biology alone. Third, the canine VH repertoire has not been
comprehensively studied. The numeration of the canine VH repertoire is limited to only
three normal dogs differing in breed from the ones used in this study. Therefore, differences
in VH gene usage between normal and lymphoma cells may be biased by factors other than
disease. Additional studies will be needed to corroborate our results.
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Expression of the VH1-44 gene predicts overall survival of cBCL and cDLBCL patients. A
comparative analysis of canine VH1-44 and its human homolog, VH3-23, indicates that this
biology may be evolutionarily conserved in hBCL. Our results identify a novel prognostic
biomarker for differential survival in cBCL patients, and this could possibly extend to
hBCL. Our findings indicate that canine patients are a representative animal model for
human BCL immunopathology.
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Kaplan Meier curves of the (A) overall survival and (B) progression-free survival in cBCL
patients with and without VH1-44 gene usage. Similarly, (C) overall survival and (D)
progression-free survival in cDLBCL with and without VH1-44 gene usage.
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Table 2
List of human VH genes that are highly homologous to canine VH1-44
Canine VH gene Human VH gene1 Homology2 Homology (%)3
VH1-44 VH3-23*04 262/293 (295) 89
VH3-23*03 262/293 (295) 89
VH3-33*03 261/292 (295) 89
VH3-23*05 261/293 (295) 89
VH3-23*01 261/293 (295) 89
VH3-33*06 260/292 (295) 89
VH3-33*01 259/291 (295) 89
VH3-NL1*01 259/292 (295) 88
VH3-21*04 259/292 (295) 88
VH3-23*02 259/293 (295) 88
1
An asterisk and a two-figure number represent allele polymorphisms for each VH family gene. *01 is the sequence selected as the reference
sequence; *02, *03, etc. are other alleles with polymorphic sequence.
2
Homology: number of identical nucleotides/ length of the best local alignment of VH1-44 and the human IGHV (the total length of VH1-44 is in
parentheses)
3
Homology: the percentage of identical nucleotides
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